20 January 2026
20 January 2026
Guardant and MSD will evaluate opportunities to develop new oncology therapies using liquid biopsy tests.
The RMAT designation is intended to expedite the development and evaluation of regenerative medicine therapies.
Optimed focuses on the global research, development, production, and distribution of devices for minimally invasive therapies.
Genmab plans to present full results at an upcoming medical meeting.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
